PLENARY SESSIONS

No documents at this time.

See descriptions of the conference plenaries here.

Educational Symposiums

  • ADVANCES IN HEOR: NEW FRONTIERS BASED ON DEVELOPMENTS IN ARTIFICIAL INTELLIGENCE

    Presentation

    Eric Q. Wu
    PhD, Managing Principal, Analysis Group, Inc., Boston, USA
  • REDUCING PAYER UNCERTAINTY BY PREDICTING DISEASE OUTCOMES AND IDENTIFYING THE RIGHT PATIENT: FACT OR FANTASY?

    Presentation

    Mark Ratcliffe
    PhD, Chief Executive Officer, PHMR Ltd, London, United Kingdom
  • AUTOMATION IN PUBLIC HEALTH DECISION MAKING: HOW FAR CAN IT GO, HOW FAR SHOULD IT GO?

    Presentation

    Hans-Peter Dauben
    MD, PhD, Secretary General at EuroScan International Network e.V., & Senior Scientist at Rheinische Fachhochschule Köln gGmbH, Cologne, Germany
  • AUTOMATION IN PUBLIC HEALTH DECISION MAKING: HOW FAR CAN IT GO, HOW FAR SHOULD IT GO?

    Presentation

    Jim Nasr
    MBA, BSc, VP, Technology & Innovation, Synchrogenix, a Certara Company, Wilmington, USA
  • AUTOMATION IN PUBLIC HEALTH DECISION MAKING: HOW FAR CAN IT GO, HOW FAR SHOULD IT GO?

    Presentation

    Sandy Allerheiligen
    PhD, SVP, Strategic Consulting, Health Economics and Education, Certara, Princeton, USA
  • HOW SHOULD WE MEASURE QUALITY OF LIFE IMPACT IN RARE DISEASE?: RECENT LEARNINGS IN SPINAL MUSCULAR ATROPHY

    Presentation

    Martina Garau
    MSc, Principal Economist, Office of Health Economics, London, United Kingdom
  • RAISING ORGANIZATIONAL FLUENCY IN REAL WORLD EVIDENCE THROUGH INTERACTIVE LEARNING TECHNIQUES

    Presentation

    David Thompson
    PhD, Senior Vice President, Syneos Health, Boston, USA
  • INDICATION-BASED PRICING; WHO WINS, WHO LOSES, AND WHERE NEXT?

    Presentation

    Adrian Towse
    MA, MPhil, Director, Office of Health Economics, London, United Kingdom
  • INDICATION-BASED PRICING; WHO WINS, WHO LOSES, AND WHERE NEXT?

    Presentation

    Francis Arickx
    Pharmacist, Head of the Directorate Reimbursement of Medicines and Pharmaceutical Policy, National Institute for Health and Disability Insurance RIZIV INAMI, Brussels, Belgium

ISSUE PANEL PRESENTATIONS

  • IP1 : GLOBAL BIOPHARMACEUTICAL INNOVATION - €”TOO MUCH, TOO LITTLE, OR BOTH?

    Presentation

    Charles E. Phelps
    PhD, MBA, University Professor and Provosts Emeritus, University of Rochester, Gualala, USA
  • IP1 : GLOBAL BIOPHARMACEUTICAL INNOVATION - €”TOO MUCH, TOO LITTLE, OR BOTH?

    Presentation

    Patricia M. Danzon
    PhD, Celia Moh Professor Emeritus, University of Pennsylvania, Philadelphia, USA
  • IP1 : GLOBAL BIOPHARMACEUTICAL INNOVATION - €”TOO MUCH, TOO LITTLE, OR BOTH?

    Presentation

    Adrian Towse
    MA, MPhil, Director, Office of Health Economics, London, United Kingdom
  • IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?

    Presentation

    Rosanna Tarricone
    MSc, PhD, Associate SDA Dean, SDA Bocconi School of Management, Milan, Italy
  • IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?

    Presentation

    Carlo Federici
    MSc, SDA Research Fellow, SDA Bocconi School of Management, MILANO, Italy
  • IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?

    Presentation

    Flora Giorgio
    PhD, Head of Sector, European Commission, Brussels, Belgium
  • IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?

    Presentation

    Jean Luc Lemercier
    Pharm.D, Corporate Vice President, EMEA, Canada and Latin America, Edwards Lifesciences, Irvine, USA
  • IP12 : WHAT DOES PATIENT-CENTERED CARE MEAN FOR MEDICINE IN THE WELFARE STATES OF EUROPE?

    Presentation

    Shelby D Reed
    PhD, Professor, Duke University, Durham, USA
  • IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?

    Presentation

    Vladimir Zah
    DPhil, Visiting Professor of Health Economics, Kozminski University, Warszawa, Poland
  • IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?

    Presentation

    Ken Redekop
    PhD, Associate Professor, Erasmus University Rotterdam, Rotterdam, Netherlands
  • IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?

    Presentation

    Katarzyna Kolasa
    PhD, Professor of Health Economics, Head of Department, Kozminski University, Warszawa, Poland
  • IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?

    Presentation

    Carl V. Asche
    PhD, Director, University of Illinois College of Medicine at Peoria, Peoria, USA
  • IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?

    Presentation

    Isabelle Durand-Zaleski
    MD, PhD, Director of the URC ECO Ile-De-France, Unité de recherche clinique en économie de la santé d’Ile-de-France, Paris, France
  • IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?

    Presentation

    Michelle Jenks
    BA, MSc, Project Director, York Health Economics Consortium, York, United Kingdom
  • IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?

    Presentation

    Petra Schnell-Inderst
    MPH, Dipl. Biol, Senior Scientist, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
  • IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?

    Presentation

    Cynthia Iglesias
    PhD, Senior Research Fellow, University of York, York, United Kingdom
  • IP15 : TRANSFORMING HEALTHCARE: THE IMPACT OF PATIENT ENGAGEMENT

    Presentation

    Suzanne Schrandt
    JD, Director, Patient Engagement, Arthritis Foundation, Atlanta, USA
  • IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?

    Presentation

    Mark Sculpher
    PhD, Professor of Health Economics, University of York, York, United Kingdom
  • IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?

    Presentation

    Sarah Garner
    PhD, Co-ordinator -- Innovation, Access and Use, World Health Organization, Geneva, Switzerland
  • IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?

    Presentation

    Jens Grueger
    PhD, Vice President and Head of Global Pricing and Market Access, Roche, Basel, Switzerland
  • IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?

    Presentation

    Steven D Pearson
    MD, MSc, President, Institute for Clinical and Economic Review, Boston, USA
  • IP17 : CHALLENGES IN THE VALUE ASSESSMENT, PRICING, AND FUNDING OF TARGETED COMBINATION THERAPIES IN ONCOLOGY

    Presentation

    David DAnko
    PhD, research leader, Corvinus University of Budapest, Budapest, Hungary
  • IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?

    Presentation

    Bettina Ryll
    MD, PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden
  • IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?

    Presentation

    Detlev Parow
    MD, MBA, Head of Pharmaceutical Department, D A K - Gesundheit, Hamburg, Germany
  • IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?

    Presentation

    Andrew Walker
    PhD, Director, Salus Alba Consulting, Glasgow, United Kingdom
  • IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?

    Presentation

    Richard Macaulay
    PhD, Senior Director, PAREXEL International, London, United Kingdom
  • IP2 : CAN PATIENT INVOLVEMENT IN EARLY DIALOGUES (EARLY SCIENTIFIC ADVICE) INCREASE THE VALUE OF THE ADVICE GIVEN?

    Presentation

    Nicholas Brooke
    BSc, Executive Director, The Synergist, Bruxelles, Belgium
  • IP20 : HOW PRIVATE HEALTH INSURANCE CAN SUPPORT THE IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN EMERGING ECONOMIES?

    Presentation

    Zoltán Kaló
    PhD, Professor of Health Economics, Syreon Research Institute, Budapest, Hungary
  • IP21 : ACCESS TO HIGHLY SPECIALISED TREATMENTS FOR RARE CONDITIONS, WHAT IS THE ROLE OF REAL WORLD EVIDENCE TO ADDRESS HTA AND PAYER UNCERTAINTY?

    Presentation

    Lieven Annemans
    PhD, MSc, Senior Full Professor of Health Economics, Ghent University, Ghent, Belgium
  • IP21 : ACCESS TO HIGHLY SPECIALISED TREATMENTS FOR RARE CONDITIONS, WHAT IS THE ROLE OF REAL WORLD EVIDENCE TO ADDRESS HTA AND PAYER UNCERTAINTY?

    Presentation

    Sheela Upadhyaya
    MSc, Associate Director - Highly Specialised Technologies, NICE - National Institute for Health and Care Excellence, London, United Kingdom
  • IP22 : ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?

    Presentation

    Mondher Toumi
    MD, PhD, MSc, Professor, Public Health, Aix-Marseille University, Marseille, France
  • IP22 : ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?

    Presentation

    Omar Dabbous
    MD, MPH, VP, AveXis, Inc, Bannockburn, USA
  • IP22 : ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?

    Presentation

    Jeroen P Jansen
    PhD, Chief Scientist, Precision Xtract, Oakland, USA
  • IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?

    Presentation

    Lotte Steuten
    PhD, MSc, Associate Professor & Director, Fred Hutchinson Institute for Cancer Outcomes, Seattle, USA
  • IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?

    Presentation

    Neil Hawkins
    PhD, CStat, Professor of HTA, University of Glasgow, Glasgow, United Kingdom
  • IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?

    Presentation

    Alec Morton
    PhD, Professor of Management Science, University of Strathclyde, Glasgow, Scotland, United Kingdom
  • IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?

    Presentation

    Laura Bojke
    PhD, Senior Research Fellow, University of York, York, United Kingdom
  • IP24 : VALUE OF DIAGNOSTIC INFORMATION: HOW TO MOVE FROM CONCEPT TO REALITY OF EVALUATING AND MEASURING THE VALUE OF DIAGNOSTIC INFORMATION

    Presentation

    Ken Mastris
    Mr, Board Member, European Cancer Patient Coalition, Brussels, Belgium
  • IP24 : VALUE OF DIAGNOSTIC INFORMATION: HOW TO MOVE FROM CONCEPT TO REALITY OF EVALUATING AND MEASURING THE VALUE OF DIAGNOSTIC INFORMATION

    Presentation

    Hendrik Koffijberg
    PhD, Associate Professor, University of Twente, Enchede, Netherlands
  • IP26 : WILL REGENERATIVE MEDICINES CHANGE THE WAY WE EVALUATE EVIDENCE, FUND INNOVATION, AND DETERMINE VALUE?

    Presentation

    Michael Epstein Epstein
    MS, Principal, Evidera, Webster, USA
  • IP27 : ADDRESSING CHALLENGES TO OPEN SCIENCE: DATA SHARING, REPLICATION, AND ROBUSTNESS OF EVIDENCE FROM REAL WORLD DATA

    Presentation

    Anna Garcia-Altes
    MSc, MPH, PhD, Researcher, Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain
  • IP27 : ADDRESSING CHALLENGES TO OPEN SCIENCE: DATA SHARING, REPLICATION, AND ROBUSTNESS OF EVIDENCE FROM REAL WORLD DATA

    Presentation

    Shirley V. Wang
    PhD, Assistant Professor of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA
  • IP27 : ADDRESSING CHALLENGES TO OPEN SCIENCE: DATA SHARING, REPLICATION, AND ROBUSTNESS OF EVIDENCE FROM REAL WORLD DATA

    Presentation

    Amr Makady
    PharmD, PhD, Policy Advisor, The National Healthcare Institute (ZIN), Diemen, Netherlands
  • IP3 : WILL MACHINES SOON MAKE HEALTH ECONOMISTS OBSOLETE?

    Presentation

    David Thompson
    PhD, Senior Vice President, Syneos Health, Boston, USA
  • IP3 : WILL MACHINES SOON MAKE HEALTH ECONOMISTS OBSOLETE?

    Presentation

    Gerry Oster
    PhD, Senior Economist, Policy Analysis Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, USA
  • IP3 : WILL MACHINES SOON MAKE HEALTH ECONOMISTS OBSOLETE?

    Presentation

    Michael Drummond
    MCom, DPhil, Professor of Health Economics, University of York, Heslington, York, United Kingdom
  • IP5 : PROVE IT WITH PROS

    Presentation

    Anke van Engen
    MSc, Senior Principal, IQVIA, Amsterdam, Netherlands
  • IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?

    Presentation

    J. Ross Maclean
    MD, PhD, Senior Vice President, Head of Medical Affairs, Precision Health Economics, Los Angeles, USA
  • IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?

    Presentation

    Louis P. Garrison
    PhD, Professor Emeritus, University of Washington, Seattle, USA
  • IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?

    Presentation

    Mark Sculpher
    PhD, Professor of Health Economics, University of York, York, United Kingdom
  • IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?

    Presentation

    Jens Grueger
    PhD, Vice President and Head of Global Pricing and Market Access, Roche, Basel, Switzerland
  • IP7 : CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?

    Presentation

    Michael Drummond
    PhD, Prof., University of York, York, United Kingdom
  • IP7 : CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?

    Presentation

    Oyvind Melien
    Department Director, Reviews and HTA, Norwegian Institute of Public Health, Oslo, Norway
  • IP8 : HTA VALUE BASED PRICING VERSUS WHO FAIR PRICING. WHICH DELIVERS UNIVERSAL HEALTH COVERAGE?

    Presentation

    Adrian Towse
    MA, MPhil, Director, Office of Health Economics, London, United Kingdom
  • IP8 : HTA VALUE BASED PRICING VERSUS WHO FAIR PRICING. WHICH DELIVERS UNIVERSAL HEALTH COVERAGE?

    Presentation

    Kalipso Chalkidou
    MD, PhD, Director Global Health Policy, Center for Global Development, London, United Kingdom
  • IP8 : HTA VALUE BASED PRICING VERSUS WHO FAIR PRICING. WHICH DELIVERS UNIVERSAL HEALTH COVERAGE?

    Presentation

    Sarah Garner
    PhD, Co-ordinator -- Innovation, Access and Use, World Health Organization, Geneva, Switzerland
  • IP9 : BACK TO THE FUTURE: SHOULD WE LIVE IN A POST-QALY WORLD?

    Presentation

    John Spoors
    BA (Hons), DipHE, Associate Director, RJW & Partners, London, United Kingdom

WORKSHOP PRESENTATIONS

  • W1 : ROADBLOCKS AND RESOLUTIONS: DEVELOPMENT OF PRO INSTRUMENTS FOR MULTINATIONAL TRIALS (Advanced Workshop)

    Presentation

    Bruce Crawford
    MPH, MA, Vice President, Syneos Health, Tokyo, Japan
  • W10 : UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS (Advanced Workshop)

    Presentation

    Olivier Chassany
    MD, PhD, Professor, University Paris-Diderot, Paris, France
  • W10 : UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS (Advanced Workshop)

    Presentation

    Donald E Stull
    PhD, Head, Data Analytics and Design Strategy, RTI Health Solutions, Durham, USA
  • W10 : UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS (Advanced Workshop)

    Presentation

    Stephanie Manson
    PhD, Senior Director, Novartis, East Hanover, USA
  • W11 : CHALLENGES AND LESSONS LEARNED FROM ELECTRONIC RECRUITMENT AND VALIDATION OF PATIENTS FOR OUTCOME RESEARCH STUDIES IN RARE DISEASES

    Presentation

    Monica Hadi
    PhD, Research Scientist, Evidera, London, United Kingdom
  • W12 : ARE MISSING DATA PROPERLY ACCOUNTED FOR IN HEALTH ECONOMICS AND OUTCOMES RESEARCH? (Advanced Workshop)

    Presentation

    Gianluca Baio
    PhD, Reader in Statistics & Health Economics, University College London, London, United Kingdom
  • W13 : ECONOMIC EVALUATION TRANSFERABILITY: A COMPARATIVE EXAMINATION OF ASSESSING MEDICAL DEVICES ACROSS THE EU IN THE CONTEXT OF NEW HTA PROPOSAL OF THE EUROPEAN COMMISSION

    Presentation

    Orsi Nagy
    PhD, Head of Sector, European Commission, Brussels, Belgium
  • W14 : PATIENT-FOCUSED DRUG DEVELOPMENT AND PATIENT-CENTERED CLINICAL CARE: WORKING TOGETHER.

    Presentation

    Robert McBurney
    PhD, Co-Principal Investigator, iConquerMS™ - the MS Patient-Powered Research Network, Accelerated Cure Project for MS, Chestnut Hill, USA
  • W15 : SURVIVAL EXTRAPOLATION: HOW TO DRAW THE LINES BEYOND THE OBSERVED DATA, IF YOU MUST

    Presentation

    Andreas Karabis
    PhD, Principal, IQVIA, Amsterdam, Netherlands
  • W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS

    Presentation

    Mark Sculpher
    PhD, Professor of Health Economics, University of York, York, United Kingdom
  • W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS

    Presentation

    Mike Baldwin
    MBA, BA, Market Access Director, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  • W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS

    Presentation

    Jerome Baddley
  • W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS

    Presentation

    Carolin Miltenburger
    MSc, PhD, Owner and Principal, Miltenburger Consulting, Berlin, Germany
  • W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)

    Presentation

    Nicholas Latimer
    MSc, PhD, Reader in Health Economics, University of Sheffield, Sheffield, United Kingdom
  • W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)

    Presentation

    Martin Scott
    MSc, Director Statistics, Numerus, Tübingen, Germany
  • W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)

    Presentation

    Melvin (Skip) Olson
    PhD, Global Head RWD Strategy and Innovation, Novartis Pharma AG, Basel, Switzerland
  • W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)

    Presentation

    Daniel Rosenberg
    PhD, Head Epidemiology & Observational Studies, Actelion Pharmaceticals Ltd, Allschwil, Switzerland
  • W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS

    Presentation

    Xavier Pouwels
    MSc, Junior researcher in Health Economics/ Phd candidate, Maastricht University Medical Centre+, Maastricht, Netherlands
  • W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS

    Presentation

    Wietske Kievit
    PhD, Post-doctoral researcher, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  • W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS

    Presentation

    Richard Grieve
    PhD, Professor of Health Economics Methodology, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS

    Presentation

    Manuela Joore
    PhD, Professor in Health Technology Assessment and Decision-Making, Maastricht University Medical Centre, Maastricht, Netherlands
  • W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES

    Presentation

    Gianluca Baio
    PhD, Reader in Statistics & Health Economics, University College London, London, United Kingdom
  • W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES

    Presentation

    Jeroen P Jansen
    PhD, Lead Scientific Advisor - Open Source Value Project, Innovation and Value Initiative, Los Angeles, USA
  • W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES

    Presentation

    Devin Incerti
    PhD, Lead Economist - Open Source Value Project, Innovation and Value Initiative, Los Angeles, USA
  • W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES

    Presentation

    Howard Thom
    BA, MSc, PhD, Research Fellow in Statistical Modelling, University of Bristol, Bristol, United Kingdom
  • W2 : CHALLENGES IN THE USE OF REAL-WORLD EVIDENCE FOR PHARMACOECONOMIC MODELLING

    Presentation

    Aurelie Millier
    PhD, Principal Consultant, Creativ-Ceutical, Paris, France
  • W20 : WHEN DO WE HAVE ENOUGH EVIDENCE TO ACCEPT MIGRATION OF PATIENT-REPORTED OUTCOME MEASURES (PROMS) FROM PAPER TO SCREEN-BASED FORMATS WITHOUT ADDITIONAL TESTING?

    Presentation

    Bill Byrom
    B.Sc., Ph.D., Vice President of Product Strategy and Innovation, CRF Health, London, United Kingdom
  • W21 : INDIRECT TREATMENT COMPARISONS: AN INTERACTIVE WORKSHOP ON CHOOSING THE RIGHT TOOL FOR THE AVAILABLE DATA

    Presentation

    Necdet Gunsoy
    MPH PhD, Manager of Analytics and Innovation for Value Evidence and Outcomes, GlaxoSmithKline (GSK), Uxbridge, United Kingdom
  • W22 : POLICY MEASURES TO MAXIMISE PATIENT ACCESS AFTER THE INTRODUCTION OF BIOSIMILAR MEDICINES IN THE OFF-PATENT BIOLOGICAL MARKET

    Presentation

    Evelien Moorkens
    MSc, PhD Researcher, KU Leuven, Leuven, Belgium
  • W22 : POLICY MEASURES TO MAXIMISE PATIENT ACCESS AFTER THE INTRODUCTION OF BIOSIMILAR MEDICINES IN THE OFF-PATENT BIOLOGICAL MARKET

    Presentation

    Andras Inotai
    PharmD, PhD, DrHabil, Principal Researcher; Assistant Professor, 1) Syreon Research Institute 2) Eötvös Loránd University (ELTE), Budapest, Hungary
  • W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)

    Presentation

    Felicitas Kuhne
    MSc, Junior Scientist, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria
  • W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)

    Presentation

    Uwe Siebert
    Prof, MPH, MSc, ScD, MD, Professor, UMIT - University for Health Sciences, Medical Informatics and Technology / Harvard T.H. Chan School of Public Health / Harvard Medical School, Boston, MA, USA, Hall i.T., Austria
  • W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)

    Presentation

    Nicholas Latimer
    PhD, Reader in Health Economics, ScHARR - University of Sheffield, Sheffield, United Kingdom
  • W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)

    Presentation

    Amanda Adler
    MD, PhD, FRCP, Chair, Addenbrooks’s Hospital/National Institute for Health and Care Excellence, Cambridge, United Kingdom
  • W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)

    Presentation

    Richard Grieve
    PhD, Professor, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)

    Presentation

    Warren Stevens
    PhD, Principal Economist, PAREXEL, Hillsborough, USA
  • W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)

    Presentation

    Neil Hawkins
    PhD, CStat, Professor of HTA, University of Glasgow, Glasgow, United Kingdom
  • W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)

    Presentation

    Anirban Basu
    PhD, Stergachis Family Endowed Professor & Director, University of Washington, Seattle, USA
  • W5 : APPLICATION OF GAMIFICATION IN HEALTHCARE AND OUTCOMES MEASUREMENT: IMPROVING TREATMENT COMPLIANCE AND RESEARCH ENGAGEMENT

    Presentation

    Michael Acquadro
  • W6 : ECONOMIC MODEL CHOICE, VALIDATION, AND SHARING: PRAGMATIC ROADMAPS FOR PHARMACOECONOMIC PRACTICE (Advanced Workshop)

    Presentation

    R. Brett Mcqueen
    PhD, Assistant Professor, University of Colorado Denver, Denver, USA
  • W6 : ECONOMIC MODEL CHOICE, VALIDATION, AND SHARING: PRAGMATIC ROADMAPS FOR PHARMACOECONOMIC PRACTICE (Advanced Workshop)

    Presentation

    Zoltan Kalo
    PhD, Professor of Health economics, Eötvös Loránd University, Budapest, Hungary
  • W8 : NOVEL APPROACHES TO COMMON CHALLENGES IN MODELLING OF SURVIVAL OUTCOMES FOR COST-EFFECTIVENESS ANALYSES IN ONCOLOGY (Advanced Workshop)

    Presentation

    Matthew Dyer
    MSc, Health Economics and Payer Analytics Director, AstraZeneca, Cambridge, United Kingdom
  • W8 : NOVEL APPROACHES TO COMMON CHALLENGES IN MODELLING OF SURVIVAL OUTCOMES FOR COST-EFFECTIVENESS ANALYSES IN ONCOLOGY (Advanced Workshop)

    Presentation

    Richard Birnie
    PhD, Principal Statistician, BresMed Health Solutions Ltd, Sheffield, United Kingdom
  • W9 : HOW TO COMMUNICATE COST-EFFECTIVENESS ANALYSIS TO A LAY AUDIENCE?

    Presentation

    Rita Faria
    MSc, Research Fellow, University of York, York, United Kingdom

ISPOR FORUMS

  • F1 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS

    Presentation

    Elisabeth Fenwick
    PhD, Senior Director, MMA, Pharmerit International, Wallingford, Oxfordshire, United Kingdom
  • F10 : PRIORITY SETTING - CRITERIA AND PROCESS OF RARE DISEASES MANAGEMENT IN CEE COUNTRIES

    Presentation

    Rasim Jusufović
    MD, PhD, Assistant Professor, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
  • F10 : PRIORITY SETTING - CRITERIA AND PROCESS OF RARE DISEASES MANAGEMENT IN CEE COUNTRIES

    Presentation

    Dragana Atanasijevic
    MD, MPH, MSc, President, Institute of Public Health of Serbia, Belgrade, Serbia
  • F10 : PRIORITY SETTING - CRITERIA AND PROCESS OF RARE DISEASES MANAGEMENT IN CEE COUNTRIES

    Presentation

    Ljubica Suturkova
    PharmD,PhD, President, Republic of Macedonia Institute of Pharmaceutical Chemistry, Skopje, Macedonia
  • F11 : THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR

    Presentation

    James F. Murray
    PhD, Research Fellow, Eli Lilly and Company, Carmel, USA
  • F12 : VALUE ASSESSMENT FRAMEWORK IN EMERGING MARKETS – EXPERIENCE FROM COUNTRIES IN THE MIDDLE EAST

    Presentation

    Gihan Hamdy El-sisi
    MSc, PhD, Head of Pharmacoeconomic Unit, Heliopolis University, Cairo, Egypt
  • F12 : VALUE ASSESSMENT FRAMEWORK IN EMERGING MARKETS – EXPERIENCE FROM COUNTRIES IN THE MIDDLE EAST

    Presentation

    Ola Ghaleb Al Ahdab
    PhD, President, Pharmacy Colleges, Abu Dhabi, United Arab Emirates
  • F12 : VALUE ASSESSMENT FRAMEWORK IN EMERGING MARKETS – EXPERIENCE FROM COUNTRIES IN THE MIDDLE EAST

    Presentation

    Kasem Akhras
    PharmD, Senior Director, The University of Illinois at Chicago, Dubai, United Arab Emirates
  • F2 : TOWARDS A VALUE FRAMEWORK FOR PRECISION MEDICINE: RECOMMENDATIONS FROM THE ISPOR PRECISION MEDICINE SPECIAL INTEREST GROUP

    Presentation

    Eric C. Faulkner
    MPH, Vice President, Evidera, Raleigh, USA
  • F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?

    Presentation

    Olha Zaliska
    PhD, DSci, Professor, Head of the Department of Management and Economy of Pharmacy, Drug Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
  • F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?

    Presentation

    Joanna Lis
    PhD, Assistant Professor, Sanofi, Warsaw, Poland
  • F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?

    Presentation

    Oresta Piniazhko
    PhD, President, Ministry of Health of Ukraine, Lviv, Ukraine
  • F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?

    Presentation

    Vladimir Zah
    PhD, Visiting Professor, Kozminski University, Warsaw Poland and Health Economist, CEO, ZRx Outcomes Research Inc., Serbia, Belgrade, Serbia
  • F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?

    Presentation

    Bertalan Ne+L123meth
    MSc, President, Syreon Research Institute, Budapest, Hungary
  • F4 : TRIANGULATING DEVELOPERS, REGULATORS AND PAYERS TO REAP REWARDS AND ADDRESS CHALLENGES WITH CURATIVE THERAPIES

    Presentation

    Shelby D Reed
    PhD, Professor, Duke University, Durham, USA
  • F4 : TRIANGULATING DEVELOPERS, REGULATORS AND PAYERS TO REAP REWARDS AND ADDRESS CHALLENGES WITH CURATIVE THERAPIES

    Presentation

    Anirban Basu
    PhD, Professor, University of Washington, Seattle, USA
  • F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?

    Presentation

    Mahmoud Diaa Elmahdawy
    PharmD, President, ISPOR Egypt Chapter, Director, Market Access and Health Economics, Novartis, Cairo, Egypt
  • F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?

    Presentation

    Redouane Soualmi
    PharmD, MSc, Pricing & Market Access Manager, Boehringer Ingelheim, Algiers, Algeria
  • F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?

    Presentation

    Tienie Stander
    MBChB, MBA, President, ISPOR South Africa Chapter & Chief Executive Officer, TCD Research FZ-LLC, Dubai, United Arab Emirates
  • F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?

    Presentation

    Daniel Asfaw Erku
    BPharm, Dip Ed, PhD(c), President, ISPOR Ethiopia Chapter, University of Gondar, Gondar, Ethiopia
  • F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES

    Presentation

    Carme Pinyol
    MD, PhD, MSc, Head of Pricing and Market Access, Southern Europe, Pierre Fabre, Barcelona, Spain
  • F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES

    Presentation

    marta Trapero Bertran
    -, Vocal Assessor, DGSSNSF, Ministry of Health, Madrid, Spain
  • F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES

    Presentation

    Josep Torrent-Farnell
    MD, PhD, Director, Drug’s Area, Catsalut, Barcelona, Spain
  • F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES

    Presentation

    Jordi Marti
    MD, President, ASEBIO, Madrid, Spain
  • F7 : HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING

    Presentation

    John E. Brazier
    PhD, MSc, Dean, University of Sheffield, Sheffield, United Kingdom
  • F8 : WHAT CAN HEALTH ECONOMICS LEARN FROM OPERATIONS RESEARCH?

    Presentation

    Praveen Thokala
    MASc, PhD, Research Fellow, The University of Sheffield, SHEFFIELD, United Kingdom
  • F9 : DIAGNOSTICS EVIDENTIARY DINOSAUR EVOLUTION: CONVENTIONAL HEALTH ECONOMICS AND MARKET ACCESS APPROACHES VS. ADVANCED ANALYTICS AS THE NEW NORM?

    Presentation

    Eric C. Faulkner
    MPH, Vice President, Evidera, Raleigh, USA

You Might Also Be Interested In...